Author

H.-e. C. Bhang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

F. Rago· 2 shared G. Elliott· 2 shared Z. Jagani· 2 shared A. Bric· 1 shared A. Kauffmann· 1 shared A. Li· 1 shared A. Vattay· 1 shared C. D. Adair· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Rago

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivApr 23, 2021

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia

F. Rago, L. U. Rodrigues, M. Bonney…·Z. Jagani

This study shows that dual BRG1/BRM ATPase inhibitors are effective against AML cell lines, revealing broad SWI/SNF dependencies and suggesting therapeutic potential.

DOI 10.1158/1541-7786.mcr-21-0390

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintOct 22, 2019

In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling

Z. Jagani, G. Chenail, K. Xiang…·Haas

This study validates novel BRM/BRG1 ATPase inhibitors as chemical probes for SWI/SNF chromatin remodeling and shows their therapeutic potential in BRG1-mut lung cancers.

DOI 10.1101/812628

humanATAC-seq

𝕏 PostBluesky